See more : Danimer Scientific, Inc. (DNMR) Income Statement Analysis – Financial Results
Complete financial analysis of Vir Biotechnology, Inc. (VIR) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Vir Biotechnology, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- Axfood AB (publ) (AXFOY) Income Statement Analysis – Financial Results
- Bebida Beverage Company (BBDA) Income Statement Analysis – Financial Results
- Tsingtao Brewery Company Limited (TSGTY) Income Statement Analysis – Financial Results
- Wintest Corp. (6721.T) Income Statement Analysis – Financial Results
- Jones Soda Co. (JSDA.CN) Income Statement Analysis – Financial Results
Vir Biotechnology, Inc. (VIR)
About Vir Biotechnology, Inc.
Vir Biotechnology, Inc., a commercial-stage immunology company, develops therapeutic products to treat and prevent serious infectious diseases. It develops Sotrovimab (VIR-7832), a SARS-CoV-2-neutralizing mAbs to treat and prevent COVID-19 infection under the Xevudy brand; VIR-2218 and VIR-3434 for the treatment of hepatitis B virus; VIR-2482 for the prevention of influenza A virus; and VIR-1111 for the prevention of human immunodeficiency virus. The company has grant agreements with Bill & Melinda Gates Foundation and National Institutes of Health; an option and license agreement with Brii Biosciences Limited and Brii Biosciences Offshore Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; license agreements with The Rockefeller University and MedImmune, Inc.; collaboration with WuXi Biologics and Glaxo Wellcome UK Ltd.; and a collaborative research agreement with GlaxoSmithKline Biologicals SA. It also has a manufacturing agreement with Samsung Biologics Co.,Ltd. for the manufacture of SARS-COV-2 antibodies; and clinical collaboration with Gilead Sciences, Inc. for chronic hepatitis B virus. Vir Biotechnology, Inc. was incorporated in 2016 and is headquartered in San Francisco, California.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|
| Revenue | 86.18M | 1.58B | 1.09B | 67.25M | 711.00K | 868.00K | 149.00K |
| Cost of Revenue | 2.77M | 146.32M | 65.87M | 301.58M | 148.47M | 100.23M | 62.51M |
| Gross Profit | 83.42M | 1.43B | 1.02B | -234.33M | -147.76M | -99.36M | -62.36M |
| Gross Profit Ratio | 96.79% | 90.74% | 93.94% | -348.48% | -20,782.14% | -11,447.12% | -41,854.36% |
| Research & Development | 589.67M | 474.65M | 448.01M | 302.41M | 148.47M | 100.23M | 62.51M |
| General & Administrative | 0.00 | 0.00 | 0.00 | 70.94M | 37.60M | 29.13M | 21.69M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 174.05M | 161.76M | 160.79M | 70.94M | 37.60M | 29.13M | 21.69M |
| Other Expenses | 0.00 | -35.33M | -8.35M | -9.12M | -7.38M | -212.00K | 83.00K |
| Operating Expenses | 767.72M | 601.09M | 600.45M | 364.23M | 178.69M | 119.56M | 81.65M |
| Cost & Expenses | 770.49M | 747.40M | 666.32M | 364.23M | 178.69M | 119.56M | 81.65M |
| Interest Income | 86.99M | 28.09M | 439.00K | 2.84M | 8.51M | 2.54M | 638.00K |
| Interest Expense | 0.00 | 183.15M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 19.45M | 15.49M | 11.98M | 8.81M | 4.52M | 2.76M | 432.00K |
| EBITDA | -664.85M | 833.07M | 420.75M | -289.80M | -173.46M | -115.94M | -81.07M |
| EBITDA Ratio | -771.47% | 59.74% | 26.01% | -441.64% | -25,032.21% | -13,356.68% | -54,406.04% |
| Operating Income | -684.31M | 833.07M | 276.89M | -296.98M | -177.98M | -118.69M | -81.50M |
| Operating Income Ratio | -794.04% | 52.71% | 25.47% | -441.64% | -25,032.21% | -13,674.19% | -54,695.97% |
| Total Other Income/Expenses | 56.11M | -78.79M | 129.05M | -1.63M | 3.45M | 2.33M | 721.00K |
| Income Before Tax | -628.19M | 754.28M | 549.80M | -298.61M | -174.53M | -116.36M | -80.78M |
| Income Before Tax Ratio | -728.93% | 47.72% | 50.58% | -444.06% | -24,546.98% | -13,405.99% | -54,212.08% |
| Income Tax Expense | -13.08M | 238.44M | 21.22M | 54.00K | 154.00K | -480.00K | -10.92M |
| Net Income | -615.06M | 515.84M | 528.58M | -298.67M | -174.68M | -115.88M | -69.85M |
| Net Income Ratio | -713.69% | 32.64% | 48.62% | -444.14% | -24,568.64% | -13,350.69% | -46,880.54% |
| EPS | -4.59 | 3.89 | 4.07 | -2.51 | -1.62 | -1.20 | -0.72 |
| EPS Diluted | -4.59 | 3.83 | 3.96 | -2.51 | -1.62 | -1.20 | -0.72 |
| Weighted Avg Shares Out | 134.13M | 132.61M | 129.88M | 119.16M | 107.65M | 96.91M | 96.91M |
| Weighted Avg Shares Out (Dil) | 134.13M | 134.81M | 133.44M | 119.16M | 107.65M | 96.91M | 96.91M |
Vir Biotechnology Announces Multiple Abstracts Highlighting New Hepatitis B and D Data Accepted for Presentation at EASL™ Congress 2023
Vir Biotechnology to Participate in the 44th Annual Goldman Sachs Global Healthcare Conference
Vir Biotechnology to Host a Virtual-Only 2023 Annual Meeting of Stockholders
Vir Biotechnology Appoints Jeff Calcagno, M.D., as Executive Vice President and Chief Business Officer
Vir Biotechnology Announces First Patient Dosed in New Phase 2 Chronic Hepatitis B Virus Trial Evaluating Combinations of VIR-2218, VIR-3434, PEG-IFNα and an NRTI
Vir Biotechnology, Inc. (VIR) Reports Q1 Loss, Tops Revenue Estimates
Vir Biotechnology Provides Corporate Update and Reports First Quarter 2023 Financial Results
Vir Biotechnology to Participate in the BofA Securities 2023 Health Care Conference
Vir Biotechnology Receives Expanded Support to Develop Its Novel T Cell Vaccine Platform with New $10 Million Grant for HIV Prevention
Vir Biotechnology to Participate in the 22nd Annual Needham Virtual Healthcare Conference
Source: https://incomestatements.info
Category: Stock Reports